Advertisement
UK markets closed

  • FTSE 100

    8,164.12
    -15.56 (-0.19%)
     

  • FTSE 250

    20,286.03
    -45.77 (-0.23%)
     

  • AIM

    764.38
    -0.09 (-0.01%)
     

  • GBP/EUR

    1.1796
    -0.0009 (-0.07%)
     

  • GBP/USD

    1.2648
    +0.0006 (+0.05%)
     

  • Bitcoin GBP

    47,673.44
    -1,013.93 (-2.08%)
     

  • CMC Crypto 200

    1,257.95
    -25.88 (-2.02%)
     

  • S&P 500

    5,460.48
    -22.39 (-0.41%)
     

  • DOW

    39,118.86
    -45.20 (-0.12%)
     

  • CRUDE OIL

    81.46
    -0.28 (-0.34%)
     

  • GOLD FUTURES

    2,336.90
    +0.30 (+0.01%)
     

  • NIKKEI 225

    39,583.08
    +241.54 (+0.61%)
     

  • HANG SENG

    17,718.61
    +2.14 (+0.01%)
     

  • DAX

    18,235.45
    +24.90 (+0.14%)
     

  • CAC 40

    7,479.40
    -51.32 (-0.68%)
     
Property :

8 UK holiday home businesses you could buy now

A holiday let could be a very sound investment, providing a decent income, capital growth and — somewhere to escape

Enliven Therapeutics to Present at Two Upcoming Investor Conferences

Enliven Therapeutics, Inc.
·1-min read
Enliven Therapeutics, Inc.
Enliven Therapeutics, Inc.

BOULDER, Colo., May 29, 2024 (GLOBE NEWSWIRE) -- Enliven Therapeutics, Inc. (Enliven) (Nasdaq: ELVN), a clinical-stage precision oncology company focused on the discovery and development of next-generation small molecule kinase inhibitors, today announced that management will present at the following investor conferences in June: 

Jefferies Global Healthcare Conference
Format: Fireside Chat
Date: Wednesday, June 5
Time: 8:30 a.m. ET

Goldman Sachs Annual Global Healthcare Conference
Format: Fireside Chat
Date: Monday, June 10
Time: 3:20 p.m. ET

Both fireside chats will be webcast live and can be accessed by visiting the investor relations section of the Company’s website at https://ir.enliventherapeutics.com/. Each webcast will be archived for a period of 30 days following the conclusion of the live event.

ADVERTISEMENT

About Enliven Therapeutics
Enliven Therapeutics is a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule inhibitors to help people with cancer not only live longer, but live better. Enliven aims to address existing and emerging unmet needs with a precision oncology approach that improves survival and enhances overall well-being. Enliven’s discovery process combines deep insights in clinically validated biological targets and differentiated chemistry to design potentially first-in-class or best-in-class therapies. Enliven is based in Boulder, Colorado.

Contact
Investors
ir@enliventherapeutics.com

Media
media@enliventherapeutics.com